Novartis | Bénéfice Avant Impôts



Pre Tax Profit Changement Date
AbbVie USD 4.81B 1.54B 2024-12
Amgen USD 3.38B 111M 2024-12
AstraZeneca USD 1.67B 162M 2024-12
Bausch Health Companies USD -21000000 69M 2024-09
Biogen USD 572.2M 118.5M 2024-12
Bristol-Myers Squibb USD 4.26B 226M 2024-12
Canopy Growth CAD -121580000 9.67M 2024-12
Corcept Therapeutics USD 161.49M 108.55M 2024-12
Drreddys Laboratories 18.74B 431M 2024-12
Eli Lilly USD 5.54B 3.83B 2024-12
Gilead Sciences USD 2.96B 112M 2024-12
GlaxoSmithKline GBP 563M 2.08B 2024-12
Glaxosmithkline USD 1.66B 1.78B 2024-12
J&J USD 5.42B 1.86B 2024-12
Merck USD 5.22B 114M 2024-12
Novartis USD 4.66B 269M 2024-12
Novartis USD 4.66B 269M 2024-12
Pacira USD 49.58M 8.89M 2024-09
Perrigo USD 151.3M 11.9M 2024-12
Pfizer USD 4.44B 2.36B 2024-12
Prestige Brands USD 80.15M 8.49M 2024-12
Roche Holding CHF 1.78B 2.33B 2024-12
Sanofi EUR 2.18B 1.33B 2024-12
Sanofi USD 2.32B 2.64B 2024-12
Supernus Pharmaceuticals USD 26.38M 45.36M 2024-12
Zoetis USD 773M 144M 2024-12



Novartis Bénéfice Avant Impôts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.